We are in great need of better preventive treatments for migraines. CGRP monoclonal antibodies appear to fulfil their early promise. At the recent annual meeting of the American Headache Society four companies presented their data and it looks very good. The drugs are very effective and are likely to help about 60% of patients and what continues to surprise is their safety. Three of the four companies have completed their final, phase 3 trials and in a few months will submit their data to the FDA. The FDA has a year to decide whether to approve them, but considering their demonstrated safety and efficacy, there is no reason why they should not be approved.
Once they are approved, one issue that may pose a problem is the cost. I mentioned this in a previous post.
